These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 15584126)
41. [ACE inhibitor or ATII receptor blocker in heart failure and myocardial infarction?]. Landmark K; Reikvam A Tidsskr Nor Laegeforen; 2005 Jan; 125(1):38-40. PubMed ID: 15643463 [TBL] [Abstract][Full Text] [Related]
42. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Targher G; Bertolini L; Zenari L; Lippi G; Pichiri I; Zoppini G; Muggeo M; Arcaro G Diabet Med; 2008 Jan; 25(1):45-50. PubMed ID: 18199131 [TBL] [Abstract][Full Text] [Related]
43. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure? Ghanem FA; Movahed A Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016 [TBL] [Abstract][Full Text] [Related]
44. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ; Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652 [TBL] [Abstract][Full Text] [Related]
45. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S; Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510 [TBL] [Abstract][Full Text] [Related]
46. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril]. Rapezzi C; Ciliberti P; Graziosi M; Riva L Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516 [TBL] [Abstract][Full Text] [Related]
47. Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors. Butler J Am J Cardiol; 2019 Dec; 124 Suppl 1():S1-S2. PubMed ID: 31741434 [No Abstract] [Full Text] [Related]
48. Journal Watch: evidence that Atorvastatin reduces the risk of stroke and myocardial infarction in patients with type 2 diabetes, but with no evidence of dyslipidaemia. Gangaidzo IT Cent Afr J Med; 2005; 51(11-12):125-6. PubMed ID: 17447346 [No Abstract] [Full Text] [Related]
49. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Daly CA; Fox KM; Remme WJ; Bertrand ME; Ferrari R; Simoons ML; Eur Heart J; 2005 Jul; 26(14):1369-78. PubMed ID: 15860521 [TBL] [Abstract][Full Text] [Related]
50. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials. Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817 [TBL] [Abstract][Full Text] [Related]
52. Sight-threatening retinopathy is associated with lower mortality in type 2 diabetic subjects: a 10-year observation study. Lövestam-Adrian M; Hansson-Lundblad C; Torffvit O Diabetes Res Clin Pract; 2007 Jul; 77(1):141-7. PubMed ID: 17178168 [TBL] [Abstract][Full Text] [Related]
53. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)]. Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513 [TBL] [Abstract][Full Text] [Related]
54. Summaries for patients. The cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for patients with diabetes. Ann Intern Med; 2005 Jul; 143(2):I21. PubMed ID: 16027445 [No Abstract] [Full Text] [Related]
55. [Remodeling with angiotensin-converting enzyme inhibitors: from GISSI to PREAMI]. Nicolosi GL Ital Heart J; 2005 Nov; 6 Suppl 7():33S-39S. PubMed ID: 16485515 [TBL] [Abstract][Full Text] [Related]
56. [Stroke and diabetes mellitus type 2. Possibilities of prevention]. Chugunova LA; Tarasov EV; Shestakova MV Ter Arkh; 2006; 78(10):21-6. PubMed ID: 17180932 [No Abstract] [Full Text] [Related]
57. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Tokmakova M; Solomon SD Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193 [TBL] [Abstract][Full Text] [Related]
58. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Manolis AJ; Iraklianou S; Pittaras A; Zaris M; Tsioufis K; Psaltiras G; Psomali D; Foussas S; Gavras I; Gavras H Am J Hypertens; 2005 Jan; 18(1):18-22. PubMed ID: 15691612 [TBL] [Abstract][Full Text] [Related]
59. [Diabetes and ischemic heart disease: specific treatment]. Raddino R; Bonadei I; Teli M; Robba D; Caretta G; Madureri A; Zanini G; Pedrinazzi C; Vizzardi E; Cas LD G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):52S-55S. PubMed ID: 19195307 [TBL] [Abstract][Full Text] [Related]
60. Statins indispensable for people with diabetes. Health News; 2003 Aug; 9(8):6. PubMed ID: 12971317 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]